Holger W Auner

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9115518/publications.pdf

Version: 2024-02-01

90 papers	3,486 citations	201385 27 h-index	155451 55 g-index
97 all docs	97 docs citations	97 times ranked	5970 citing authors

#	Article	IF	Citations
1	The innate sensor ZBP1-IRF3 axis regulates cell proliferation in multiple myeloma. Haematologica, 2022, 107, 721-732.	1.7	17
2	Systems medicine dissection of chr1q-amp reveals a novel PBX1-FOXM1 axis for targeted therapy in multiple myeloma. Blood, 2022, 139, 1939-1953.	0.6	15
3	Ixazomib with cyclophosphamide and dexamethasone in relapsed or refractory myeloma: MUKeight phase II randomised controlled trial results. Blood Cancer Journal, 2022, 12, 52.	2.8	8
4	Efficacy and tolerability of <scp>onceâ€weekly</scp> selinexor, bortezomib, and dexamethasone in comparison with standard <scp>twiceâ€weekly</scp> bortezomib and dexamethasone in previously treated multiple myeloma with renal impairment: Subgroup analysis from the <scp>BOSTON</scp> study. American Journal of Hematology, 2022, 97, .	2.0	7
5	Systems level profiling of chemotherapy-induced stress resolution in cancer cells reveals druggable trade-offs. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	18
6	Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma. Journal of Hematology and Oncology, 2021, 14, 59.	6.9	11
7	Carfilzomib or bortezomib in combination with cyclophosphamide and dexamethasone followed by carfilzomib maintenance for patients with multiple myeloma after one prior therapy: results from a multicenter, phase II, randomized, controlled trial (MUKfive). Haematologica, 2021, 106, 2694-2706.	1.7	6
8	Effects of refractory status to lenalidomide on safety and efficacy of selinexor, bortezomib, and dexamethasone (XVd) versus bortezomib and dexamethasone (Vd) in patients with previously treated multiple myeloma.. Journal of Clinical Oncology, 2021, 39, 8024-8024.	0.8	2
9	Survival among older patients with previously treated multiple myeloma treated with selinexor, bortezomib, and dexamethasone (XVd) in the BOSTON study.. Journal of Clinical Oncology, 2021, 39, 8019-8019.	0.8	2
10	Effect of age and frailty on the efficacy and tolerability of onceâ€weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma. American Journal of Hematology, 2021, 96, 708-718.	2.0	16
11	Peripheral neuropathy symptoms, pain, and functioning in previously treated multiple myeloma patients treated with selinexor, bortezomib, and dexamethasone. American Journal of Hematology, 2021, 96, E383-E386.	2.0	7
12	Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk. American Journal of Hematology, 2021, 96, 1120-1130.	2.0	15
13	Chromatin-based, in cis and in trans regulatory rewiring underpins distinct oncogenic transcriptomes in multiple myeloma. Nature Communications, 2021, 12, 5450.	5.8	19
14	Brd2/4 and Myc regulate alternative cell lineage programmes during early osteoclast differentiation inÂvitro. IScience, 2021, 24, 101989.	1.9	13
15	Guidelines for the use and interpretation of assays for monitoring autophagy (4th) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 182	4.3	1,430
16	Results from a multicenter, noninterventional registry study for multiple myeloma patients who received stem cell mobilization regimens with and without plerixafor. Bone Marrow Transplantation, 2020, 55, 356-366.	1.3	12
17	Time from first symptom onset to the final diagnosis of multiple myeloma (MM) â€“ possible risks and future solutions: retrospective and prospective â€˜Deutsche Studiengruppe MMâ€™ (DSMM) and â€˜European Myeloma Networkâ€™ (EMN) analysis. Leukemia and Lymphoma, 2020, 61, 875-886.	0.6	12
18	Proteasome inhibition in multiple myeloma: lessons for other cancers. American Journal of Physiology - Cell Physiology, 2020, 318, C451-C462.	2.1	21

#	Article	IF	Citations
19	The MUK eight protocol: a randomised phase II trial of cyclophosphamide and dexamethasone in combination with ixazomib, in relapsed or refractory multiple myeloma (RRMM) patients who have relapsed after treatment with thalidomide, lenalidomide and a proteasome inhibitor. Trials, 2020, 21, 826.	0.7	3
20	Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial. Lancet, The, 2020, 396, 1563-1573.	6.3	188
21	Once Weekly Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Twice Weekly Bortezomib and Dexamethasone (Vd) in Relapsed or Refractory Multiple Myeloma: High-Risk Cytogenetic Risk Planned Subgroup Analyses from the Phase 3 Boston Study. Blood, 2020, 136, 35-36.	0.6	3
22	Once Weekly Selinexor, Bortezomib, and Dexamethasone Versus Twice Weekly Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Age and Frailty Subgroup Analyses from the Phase 3 Boston Study. Blood, 2020, 136, 17-18.	0.6	3
23	Impact of Prior Therapies on the Safety and Efficacy of Once Weekly Selinexor, Bortezomib, and Dexamethasone Compared with Twice Weekly Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Results from the Boston Study. Blood, 2020, 136, 50-52.	0.6	1
24	Weekly selinexor, bortezomib, and dexamethasone (SVd) versus twice weekly bortezomib and dexamethasone (Vd) in patients with multiple myeloma (MM) after one to three prior therapies: Initial results of the phase III BOSTON study.. Journal of Clinical Oncology, 2020, 38, 8501-8501.	0.8	21
25	Effect of Prior Treatment with Proteasome Inhibitors on the Efficacy and Safety of Once-Weekly Selinexor, Bortezomib, and Dexamethasone in Comparison with Twice-Weekly Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Subgroup Analysis from the Boston Study. Blood, 2020, 136, 48-50.	0.6	0
26	Peripheral Neuropathy Symptoms, Pain and Functioning in Relapsed or Refractory Multiple Myeloma Patients Treated with Selinexor, Bortezomib, and Dexamethasone. Blood, 2020, 136, 39-41.	0.6	1
27	The coordinated action of VCP/p97 and GCN2 regulates cancer cell metabolism and proteostasis during nutrient limitation. Oncogene, 2019, 38, 3216-3231.	2.6	33
28	Preclinical toxicology and safety pharmacology of the first-in-class GADD45Î²/MKK7 inhibitor and clinical candidate, DTP3. Toxicology Reports, 2019, 6, 369-379.	1.6	15
29	Prevention, monitoring and treatment of cardiovascular adverse events in myeloma patients receiving carfilzomib A consensus paper by the European Myeloma Network and the Italian Society of Arterial Hypertension. Journal of Internal Medicine, 2019, 286, 63-74.	2.7	42
30	Clinical proof of concept for a safe and effective <scp>NF</scp>â€ºBâ€targeting strategy in multiple myeloma. British Journal of Haematology, 2019, 185, 588-592.	1.2	15
31	Muktwelve: A Randomized Phase II Trial of Selinexor, Cyclophosphamide and Prednisolone Vs Cyclophosphamide and Prednisolone in Relapsed or Refractory Multiple Myeloma (RRMM) Patients. Blood, 2019, 134, 5552-5552.	0.6	1
32	Integrated Systems Level Examination of Proteasome Inhibitor Stress Recovery in Myeloma Cells Reveals Druggable Vulnerabilities Linked to Multiple Metabolic Processes. Blood, 2019, 134, 1818-1818.	0.6	0
33	PBX1 Co-Operates with FOXM1 to Regulate Myeloma Cell Proliferation and to Define an Ultra High-Risk chr1q Gain Myeloma Patient Subgroup. Blood, 2019, 134, 3760-3760.	0.6	0
34	Myc and Bet Proteins Orchestrate the Early Regulatory Genome Changes Required for Osteoclast Lineage Commitment. Blood, 2019, 134, 4329-4329.	0.6	0
35	Distinct Chromatin Accessibility Changes, Aberrant Transcription Factor Networks Combined with Novel Oncogenic Enhancers Characterise Myeloma-Initiating Genetic Events. Blood, 2019, 134, 1769-1769.	0.6	0
36	Novel ZBP1-IRF3 Dependency in Multiple Myeloma Mediated By IRF3-Driven Regulation of Cell Cycle Genes. Blood, 2019, 134, 2521-2521.	0.6	0

#	Article	IF	Citations
37	Melphalan 140 mg/m ² or 200 mg/m ² for autologous transplantation in myeloma: results from the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study. A report by the EBMT Chronic Malignancies Working Party. Haematologica, 2018, 103, 514-521.	1.7	70
38	Câ€•reactive protein prior to myeloablative allogeneic haematopoietic cell transplantation identifies patients at risk of earlyâ€•and longâ€•term mortality. British Journal of Haematology, 2018, 180, 889-892.	1.2	6
39	ER stress and cancer: The FOXO forkhead transcription factor link. Molecular and Cellular Endocrinology, 2018, 462, 67-81.	1.6	36
40	From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives. Haematologica, 2018, 103, 197-211.	1.7	110
41	Bi-directional cell-pericellular matrix interactions direct stem cell fate. Nature Communications, 2018, 9, 4049.	5.8	90
42	The HDAC6 inhibitor C1A modulates autophagy substrates in diverse cancer cells and induces cell death. British Journal of Cancer, 2018, 119, 1278-1287.	2.9	36
43	European Myeloma Network recommendations on tools for the diagnosis and monitoring of multiple myeloma: what to use and when. Haematologica, 2018, 103, 1772-1784.	1.7	86
44	Neighboring cells override 3D hydrogel matrix cues to drive human MSC quiescence. Biomaterials, 2018, 176, 13-23.	5.7	38
45	More convenient proteasome inhibition for improved outcomes. Lancet Oncology, The, 2018, 19, 856-858.	5.1	3
46	Cardiovascular adverse events in modern myeloma therapy â€“ Incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA). Haematologica, 2018, 103, 1422-1432.	1.7	70
47	Differential Regulation of Human Bone Marrow Mesenchymal Stromal Cell Chondrogenesis by Hypoxia Inducible Factor-1Î± Hydroxylase Inhibitors. Stem Cells, 2018, 36, 1380-1392.	1.4	51
48	An engineered, quantifiable in vitro model for analysing the effect of proteostasis-targeting drugs on tissue physical properties. Biomaterials, 2018, 183, 102-113.	5.7	6
49	Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN). Leukemia, 2018, 32, 1697-1712.	3.3	83
50	Maintenance with Carfilzomib Following Carfilzomib, Cyclophosphamide and Dexamethasone at First Relapse or Primary Refractory Multiple Myeloma (MM) on the Phase 2 Muk Five Study: Effect on Minimal Residual Disease. Blood, 2018, 132, 802-802.	0.6	6
51	Carfilzomib Versus Bortezomib in Combination with Cyclophosphamide and Dexamethasone for Treatment of First Relapse or Primary Refractory Multiple Myeloma (MM): Outcomes Based on Genetic Risk and Long Term Follow up of the Phase 2 Muk Five Study. Blood, 2018, 132, 306-306.	0.6	3
52	A phase 3 randomized, controlled, open-label study of selinexor, bortezomib, and dexamethasone (SVd) versus bortezomib and dexamethasone (Vd) in patients with relapsed or refractory multiple myeloma (RRMM).. Journal of Clinical Oncology, 2018, 36, TPS8056-TPS8056.	0.8	2
53	Clustering Analysis of Myeloma Clone Phenotype Is Informative for Disease Heterogeneity and Prognosis at Relapse. Blood, 2018, 132, 4492-4492.	0.6	0
54	Plerixafor effectively rescues biosimilar G-CSF-alone-based stem cell mobilisation failures. Cytotherapy, 2017, 19, S77.	0.3	0

#	Article	IF	Citations
55	Analysis of hematopoietic recovery after autologous transplantation as method of quality control for long-term progenitor cell cryopreservation. Bone Marrow Transplantation, 2017, 52, 1599-1601.	1.3	14
56	Carfilzomib, Cyclophosphamide and Dexamethasone (KCD) Versus Bortezomib, Cyclophosphamide and Dexamethasone (VCD) for Treatment of First Relapse or Primary Refractory Multiple Myeloma (MM): First Final Analysis of the Phase 2 Muk Five Study. Blood, 2017, 130, 835-835.	0.6	6
57	Stem cell transplantation in multiple myeloma and other plasma cell disorders (report from an EBMT) Tj ETQq1 1 0.784314 rgBT /Ove	0.6	7
58	Autologous haematopoietic cell transplantation in elderly patients with multiple myeloma. British Journal of Haematology, 2015, 171, 453-462.	1.2	27
59	Inadequate fine-tuning of protein synthesis and failure of amino acid homeostasis following inhibition of the ATPase VCP/p97. Cell Death and Disease, 2015, 6, e2031-e2031.	2.7	28
60	Cutaneous presentation of an aggressive plasmablastic neoplasm indiscriminate between lymphoma and myeloma. Annals of Hematology, 2015, 94, 691-692.	0.8	4
61	Bortezomib Amplifies Effect on Intracellular Proteasomes by Changing Proteasome Structure. EBioMedicine, 2015, 2, 642-648.	2.7	12
62	Trends in autologous hematopoietic cell transplantation for multiple myeloma in Europe: increased use and improved outcomes in elderly patients in recent years. Bone Marrow Transplantation, 2015, 50, 209-215.	1.3	108
63	Recent advances and future directions in targeting the secretory apparatus in multiple myeloma. British Journal of Haematology, 2015, 168, 14-25.	1.2	37
64	Cancer-Selective Targeting of the NF-Î²B Survival Pathway in Multiple Myeloma with the GADD45Î²/MKK7 Inhibitor, DTP3. Blood, 2015, 126, 868-868.	0.6	3
65	Abstract 1261: Comprehensive failure of intracellular protein homeostasis kills myeloma and solid cancer cells following VCP/p97 inhibition. , 2015, , .		0
66	Age-related trends in utilization and outcome of autologous haematopoietic cell transplantation for multiple myeloma.. Journal of Clinical Oncology, 2014, 32, 8592-8592.	0.8	0
67	Which lumen is the source of catheter-related bloodstream infection in patients with multi-lumen central venous catheters?. Infection, 2013, 41, 49-52.	2.3	22
68	Reduced intensity-conditioned allogeneic stem cell transplantation for multiple myeloma relapsing or progressing after autologous transplantation: a study by the European Group for Blood and Marrow Transplantation. Bone Marrow Transplantation, 2013, 48, 1395-1400.	1.3	37
69	Salvage autologous stem cell transplantation for multiple myeloma relapsing or progressing after up-front autologous transplantation. Leukemia and Lymphoma, 2013, 54, 2200-2204.	0.6	39
70	Combined Inhibition of p97 and the Proteasome Causes Lethal Disruption of the Secretory Apparatus in Multiple Myeloma Cells. PLoS ONE, 2013, 8, e74415.	1.1	45
71	Antimicrobial therapy of febrile complications after high-dose chemotherapy and autologous hematopoietic stem cell transplantationâ€"guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Annals of Hematology, 2012, 91, 1161-1174.	0.8	40
72	Autologous haematopoietic stem cell transplantation in multiple myeloma patients from ethnic minority groups in an equal access healthcare system. British Journal of Haematology, 2012, 157, 125-127.	1.2	8

#	Article	IF	Citations
73	Third Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma. Blood, 2012, 120, 4548-4548.	0.6	0
74	Tandem Autologous Stem Cell Transplantation in Chemorefractory Multiple Myeloma. Blood, 2012, 120, 4554-4554.	0.6	0
75	High rate of stem cell mobilization failure after thalidomide and oral cyclophosphamide induction therapy for multiple myeloma. Bone Marrow Transplantation, 2011, 46, 364-367.	1.3	16
76	LACEâ€conditioned autologous stem cell transplantation for relapsed or refractory diffuse large Bâ€cell lymphoma: treatment outcome and risk factor analysis from a single centre. Hematological Oncology, 2011, 29, 75-80.	0.8	9
77	The life span of short-lived plasma cells is partly determined by a block on activation of apoptotic caspases acting in combination with endoplasmic reticulum stress. Blood, 2010, 116, 3445-3455.	0.6	46
78	Optimizing patient selection for myeloablative allogeneic hematopoietic cell transplantation in chronic myeloid leukemia in chronic phase. Blood, 2010, 115, 4018-4020.	0.6	56
79	Preconditioning Level of C-Reactive Protein and Disease Stage Are Key Prognostic Factors In Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation.. Blood, 2010, 116, 3488-3488.	0.6	0
80	Second Autologous Stem Cell Transplantation Is Effective Salvage Therapy for Relapsed Multiple Myeloma.. Blood, 2009, 114, 1229-1229.	0.6	2
81	Ethnic Disparity in Access to Stem Cell Transplantation for Multiple Myeloma.. Blood, 2009, 114, 1781-1781.	0.6	0
82	The Combination of Cyclophosphamide and Thalidomide During Induction Therapy for Multiple Myeloma Results in a High Rate of Stem Cell Mobilization Failure.. Blood, 2009, 114, 2147-2147.	0.6	0
83	Optimizing Patient Selection for Allogeneic Stem Cell Transplantation in Chronic Myeloid Leukemia.. Blood, 2009, 114, 3392-3392.	0.6	4
84	Oral and IntestinalCandidaColonization in Patients Undergoing Hematopoietic Stemâ€Cell Transplantation. Journal of Infectious Diseases, 2008, 198, 150-153.	1.9	27
85	ER Stress and Inhibition of Key Apoptotic Caspases Regulate the Life Span of Short-Lived Plasma Cells. Blood, 2008, 112, 2554-2554.	0.6	12
86	A novel role for the Aurora B kinase in epigenetic marking of silent chromatin in differentiated postmitotic cells. EMBO Journal, 2007, 26, 4657-4669.	3.5	52
87	Two Transforming C-RAF Germ-Line Mutations Identified in Patients with Therapy-Related Acute Myeloid Leukemia. Cancer Research, 2006, 66, 3401-3408.	0.4	84
88	Two Novel Activating Germline Mutations of the C-RAF Proto-Oncogene Predisposing to Solid Tumors and Therapy-Related Acute Myeloid Leukemia.. Blood, 2004, 104, 3370-3370.	0.6	0
89	Antimicrobial therapy of febrile complications after high-dose chemo-/radiotherapy and autologous hematopoietic stem cell transplantation. Annals of Hematology, 2003, 82, S167-S174.	0.8	44
90	Two case studies of chronic idiopathic neutropenia preceding acute myeloid leukaemia. , 1999, 105, 431.		2